Sigma Planning Corp
VKTX icon

Sigma Planning Corp’s Viking Therapeutics VKTX Stock Holding History

Sigma Planning Corp’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$430K Sell
13,179
-42
-0.3% -$1.46K 0.01% 911
2026
Q2 		$516K Sell
13,221
-479
-3% -$15.5K 0.01% 899
2026
Q1 		$446K Buy
13,700
+5,940
+77% +$191K 0.01% 885
2025
Q4 		$273K Buy
+7,760
New +$275K 0.01% 1080
2024
Q4 		– Sell
-15,119
Closed -$957K – 1257
2024
Q3 		$957K Buy
+15,119
New +$887K 0.03% 517

Other funds holding VKTX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Concurrent Investment Advisors
Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return
TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $530M AUM 95.29% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Sigma Planning Corp's VKTX Position: Q3 2026 in Review

Sigma Planning Corp reduced its Viking Therapeutics (VKTX) stake by 0.32% in Q3 2026, selling an estimated $1.46K and leaving 13,179 shares worth $430K. The position accounts for 0.01% of the portfolio, ranked #911.

Sigma Planning Corp first reported a position in VKTX in Q3 2024 and has held it in 5 quarters since. The position peaked at $957K in Q3 2024. 188 funds tracked by Wall St. Rank hold VKTX as of Q3 2026.

  • Sigma Planning Corp held 13,179 shares of Viking Therapeutics worth $430K as of Q3 2026.
  • Sigma Planning Corp sold 42 Viking Therapeutics shares in Q3 2026, an estimated $1.46K.
  • Viking Therapeutics made up 0.01% of Sigma Planning Corp's portfolio in Q3 2026, its #911 holding.
  • Sigma Planning Corp first reported a position in Viking Therapeutics in Q3 2024 and has held it in 5 quarters since.
  • Sigma Planning Corp's Viking Therapeutics position peaked at $957K in Q3 2024.
  • 188 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2026.

Based on Sigma Planning Corp's 13F filing for Q3 2026, filed 23 Oct 2026.